Healthcare Industry News:  Age-related Macular Degeneration 

Biopharmaceuticals Ophthalmology Product Launch

 News Release - June 16, 2016

Valeant Pharmaceuticals Announces Launch Of New PreserVision(R) AREDS 2 Formula + Multivitamin

Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience

LAVAL, Quebec, June 16, 2016 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, launched new PreserVision® AREDS 2 Formula + Multivitamin. PreserVision® is the #1 doctor-recommended eye vitamin brand specially formulated for people with moderate to advanced Age-related Macular Degeneration.

The 2-in-1 formula helps make it simpler for consumers to take their supplements by reducing the number of pills taken each day and is the first leading brand to combine the National Eye Institute recommended AREDS2 nutrient formula with other essential vitamins and minerals typically found in daily multivitamins. PreserVision® AREDS 2 Formula + Multivitamin is beta carotene-free and contains a high level of Vitamin D to support the needs of older adults.

"We are proud that this new formula directly responds to consumer feedback and data and can create more convenience for those we serve," said Joseph C. Papa, chairman and chief executive officer. "The launch of PreserVision® AREDS 2 Formula + Multivitamin adds to Bausch + Lomb's long history of delivering innovation to eye health and underscores Valeant's commitment to inventive solutions that address consumers' healthcare needs."

The new PreserVision® AREDS 2 Formula + Multivitamin is now available in major retailers, including Walgreens, Rite Aid, Kroger and Amazon.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

Forward-looking Statements

This press release contains forward-looking statements. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

PreserVision is a registered trademark of Bausch & Lomb Incorporated or its affiliates. AREDS and AREDS2 are registered trademarks of The U.S. Department of Health and Human Services (HHS).

Source: Valeant Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.